40 results about "Inhaled drug" patented technology

A system and method for determining a minimum effective dose of an inhaled drug for an individual patient at a given time. The system includes an apparatus to measure a performance measurement of the patient and a data processor capable of communication with the apparatus. The data processor provides a computed minimum effective dose for the individual patient by applying a predetermined rule the performance measurement. The method includes measuring a performance measurement of the patient, communicating the performance measurement to a data processor and computing a minimum effective dose for the patient by applying a predetermined rule to the performance measurement within the data processor.

The present invention is directed to a device for monitoring the usage of inhaled drugs by a patient. The device includes an inhaler, a use sensor, a microprocessor, a wireless transmitter and a battery compartment. These components allow information concerning drug usage to be transmitted to health care personnel that can evaluate the data to determine whether there are changes in drug usage characteristics that are indicative of an impending acute attack. The invention includes not only the device, but also the systems and methods in which the device is employed.

The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.

A system, method and apparatus for providing positive confirmation of inhaled drug delivery by light or radiation attenuation at point-of-use is disclosed, including a tube adapted to be coupled at an outlet to an inhaler; a light or radiation source coupled to the tube; and a light or radiation detector coupled to the tube, where the source transmits light or radiation along a path intersecting a path of an emission such as a drug dose emitted from the inhaler, and where the detector receives the light or radiation from the source.

The invention is directed to a method for determining the total amount of liquid medicament containing an active drug substance to be aerosolized and inhaled by a patient in order to deliver a pharmaceutically effective amount (“PEA”) of said drug to the respiratory tract of said patient comprising: A) aerosolizing a measured amount of said medicament liquid containing a known amount of drug (“Aerosolized Dose”) using an aerosolization means connected to said patient via an inhalation tube and an exhalation tube; wherein said exhalation tube contains a filter means and wherein said Aerosolized Dose is less than said PEA of said drug; B) administering said aerosol to the respiratory tract of said patient via said inhalation tube; C) allowing the patient to exhale through said exhalation tube containing said filter wherein any exhaled drug is trapped on said filter; D) measuring the reflectance of the color on the filter media contained in said exhalation filter using a reflectance spectrophotometer to determine the amount of drug on said exhalation filter (“Exhaled Dose”); E) determining the actual dose delivered to said patient (“Delivered Dose”) as follows: Aerosolized Dose minus Trapped Dose minus Exhaled Dose=Delivered Dose, where the Trapped Dose is the amount of drug trapped in the inhalation tube; and F) calculating the total amount of liquid medicament to be aerosolized (“Total Aerosolized Dose”) by multiplying the PEA by the result of dividing the Delivered Dose by the Aerosolized Dose; wherein a solution or suspension of the drug is colored when viewed by the human eye or wherein the drug reacts with a reagent on the filter media of said filter means to produce a color.

A thermally modulating inhalable medicament delivery device may deliver an inhalable medicament as an aerosol, vapor, or partial aerosol and partial vapor mixture. The inhalable medicament may be delivered to a target in a subject. Described herein are devices, systems, and methods for delivering an inhalable medicament to a subject.

A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.

An auxiliary chamber for inhaled-drugs includes a hollow tube body and a hollow side tube; and a unidirectional air valve which only allows air from an inlet flowing to an outlet end is located at the inlet end of the hollow tube body, wherein the outlet end of the hollow tube body is connected to an endotracheal tube. The hollow side tube connects with a lateral hole of the hollow tube body at one end, and a special universal adapter at the other end. The special universal adapter has a small through hole which is used to accommodate an inhaler therein to release inhaled drugs in the inhaler into the hollow tube body, and the inhaled drugs moves from the inlet end with air flow to the outlet end after entering the hollow tube body to help patients with respiratory failure take medicine.

The invention discloses an inhalation preparation containing calcitriol and budesonide and a preparation method thereof. The inhalation preparation containing calcitriol and budesonide comprises calcitriol and budesonide as active components and one or more pharmaceutic adjuvants suitable for inhaled drugs, wherein, the weight ratio of calcitriol to budesonide is 100-800:1. The inhalation preparation containing calcitriol and budesonide can be used for treating bronchial diseases in humans or mammals.

The invention relates to a fog control inhalation device. The fog control inhalation device comprises a fog control chamber, an atomization assembly, an adsorption assembly, a communication assembly and a negative pressure generation assembly, wherein a fixed opening and a connection opening are formed in the fog control chamber; the atomization assembly is arranged in the fog control chamber; theatomization assembly comprises a suction nozzle and an inhalation drug channel positioned on the suction nozzle; the suction nozzle is arranged at the fixed opening; the atomization assembly can be used for atomizing a medicine solution and outputting liquid drops formed by atomization to the outer part of the fog control chamber through the suction nozzle; the adsorption assembly is arranged inthe fog control chamber and is used for adsorbing drug particles in inhalation gas which is inhaled into the fog control chamber through the inhalation drug channel; one end of the communication assembly is connected with the connection opening; the negative pressure generation assembly is connected with the other end of the communication assembly; and the negative pressure generation assembly canbe used for driving the inhalation gas in the fog control chamber to flow out from the communication assembly, so that negative pressure is formed in the fog control chamber. A patient can hold the fog control chamber to inhale drugs, so that the convenience and comfort of utilization are improved; the amount of the drugs exhaled by the patient and the dosage of effective drugs which actually enter the body of the patient can be counted and known.

An apparatus and method are provided for administering an inhaled drug to a person while simultaneously administering oxygen from a medical oxygen mask. The inhaled drug is from a pressurized metered dose inhaler (MDI), employing an extender tube about 3-10 cm long that fits into or over the mouthpiece of the inhaler. The MDI with extender tube is inserted into the mask and positioned so that the plume of drug travels through the extender when the MDI is actuated and is directed to just inside the mouth of the person. In an embodiment, an exhalation filter is provided to prevent contamination from infectious agents in the exhaled air from the person.

The invention relates to a sevoflurane based tranquilizer which comprises a drug and a drug carrier. The drug refers to sevoflurane. The drug carrier comprises a water absorbing material and a casing; the water absorbing material is used for carrying sevoflurane and the casing is used for covering the water absorbing material for preventing sevoflurane from volatilizing; the casing is provided with a slit, the slit is provided with a sealing unit, and sevoflurane volatilizes from the slit during treatment with the tranquilizer. The sevoflurane based tranquilizer is an inhaled drug for people to take in a breathing way, has quick action for reducing stress or tension, has low side effect, is extincted rapidly after taking effect, and has no influence on daily life and work of people taking the tranquilizer. Besides, the sevoflurane based tranquilizer is free of pungent smel and avoids tracheospasm or bronchospasm, and can be applied to sleeping induction for children.

The invention relates to a gaseous inhalable medicament containing xenon or N2O as active ingredient for use by inhalation for preventing and/or for treating neuropathic pain or pains caused by at least one cancer chemotherapy substance administered to a patient suffering from cancer, in particular a patient suffering from breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, rectal cancer or a gastric cancer or cancer of the upper aerodigestive tracts. The cancer chemotherapy substance contains one or more compounds chosen from platinum salts, taxanes, alkaloids, thalidomide and bortezomib, in particular paclitaxel, docetaxel or oxaliplatin. The effective volume proportion of nitrous oxide or of xenon is between 5 and 70%.

The invention relates to the field of inhalant devices, in particular to an inhalant device favorable for inhalant to enter deep part of lung. The device comprises a shell, the shell is provided witha storage part used for containing a medicine storage tank and an inhalation part used for inhaling medicine by a patient. The inhalant device further comprises a threshold switch, the threshold switch has a braking state and an opening state, the threshold value of the threshold switch is matched with the value of negative pressure generated in the inhalation part when the patient inhales from the inhalation part, and when the threshold switch is in the braking state, the medicine is stopped, so that the patient cannot inhale the medicine through the inhalation part; and when the value of thenegative pressure generated when the patient inhales from the inhalation part is equal to or larger than the threshold value, the threshold value switch is changed from the braking state to the opening state and kept in the opening state, and the patient can inhale the medicine from the inhalation part. In the scheme of the invention, the medicine can enter the lung at a relatively high flow rate, so that a good medicine supply effect and a good treatment effect can be achieved, and the adverse reaction risk of medicament use is greatly reduced.

The invention provides a dry powder inhalant matched with a pollen-shaped saccharide carrier as well as preparation and application methods thereof. The dry powder inhalant comprises a ternary mixed component and the ternary mixed component comprises the following components: 0.01 to 2 parts of an effective medical component (with a preferred aerodynamic median diameter of 0.5 to 5 microns), 0 to 20 parts of a saccharide rough powder carrier (with a preferred aerodynamic median diameter of 10 to 100 microns) and 0 to 20 parts of a saccharide fine powder carrier (with a preferred aerodynamic median diameter of 1 to 10 microns), wherein the saccharide rough powder carrier and/or the saccharide fine powder carrier adopts prepared pollen-shaped saccharide carrier grains (the grains have rough surfaces and more pores inside and have a BET pore surface area of 10m<2>/g to 60m<2>/g; the density of the saccharide rough powder carrier is preferably 1 to 3 times as much as that of the saccharide fine powder carrier; the grain diameter of the saccharide rough powder carrier is preferably 5 to 10 times as much as that of the saccharide fine powder carrier; the fine powder distribution ratio (FPF) of the dry powder inhalant is 10%-50%. By adopting the preparation and application methods provided by the invention, higher drug loading amount, respiratory tract transportation capability and stability of inhaled drugs are realized and the dry powder inhalant has a better inhaled drug curative effect.

The invention relates to the field of inhalant devices, and specifically relates to an inhalant device. The inhalant device comprises a shell, wherein a storage part for placing a drug storing pot andan inhalation part for a patient to inhale a medicament are arranged on the shell, and a medicament cavity communicating with the inhalation part is further formed in the shell and cooperates with the drug storing pot, and the medicament enters the medicament cavity when being sprayed from the drug storing pot; and a detection device for detecting the dose of the medicament in the medicament cavity is arranged on the inhalation part. The inhalant device provided by the invention can be used for monitoring the actual dose of the medicament inhaled by a patient, and when a detection result displays that the medicament is remained in the medicament cavity, the residual medicament can be inhaled by the patient again until being completely inhaled, so that the sufficient dose of the medicamentis guaranteed, and a good treatment effect is guaranteed.

The invention relates to the field of inhalant devices, in particular to an inhalant device with adjustable inhalation force. The device comprises an inhalation part for inhaling a medicament by a patient, and further comprises a threshold switch with a braking state and an opening state; a threshold of the threshold switch is matched with the value of negative pressure generated in the inhalationpart when the patient inhales air by the inhalation part, and when the threshold switch is in the braking state, the medicament is stopped, so that the patient cannot inhale the medicament by the inhalation part; when the value of the negative pressure generated when the patient inhales the air by the inhalation part is equal to or larger than the threshold, the threshold switch is converted to be in the opening state from the braking state and kept in the opening state, so that the patient can inhale the medicament by the inhalation part; and the threshold of the threshold switch is adjustable. According to the inhalant device, the good medicine supply effect and the good treatment effect can be achieved, the adverse reaction risk of medicine use is greatly reduced, and the inhalant device can be suitable for patients with different physical conditions.

The invention relates to the field of inhalant devices, in particular to an inhalation device capable of monitoring the inhalation amount and used for an inhalant device. The inhalation device is usedfor being matched with the inhalant device for use. The inhalation device comprises a detection part for displaying the inhaled medicament amount of a patient; and the inhalation device is detachablyconnected with the inhalant device. According to the scheme, the detection part can be of a detection structure formed by combining an existing sensor capable of detecting the medicament amount and adisplayer, and can also be of a structure for displaying the inhaled medicament amount of the patient in other forms. The inhalation device is provided with the detection part for displaying the inhaled medicament amount of the patient, so that the actual inhaled amount of the patient is monitored.

The invention provides methods, devices and compositions for use in inhalation therapy of neonates, infants or children younger than 12 years, e.g. from 1 to 8 years, suffering from a disease, optionally a pulmonary disease, such as asthma, by which high amounts of inhaled drugs are directed to the small airways of the peripheral lungs of neonates, infants and children using slow, controlled flow rates and pre-set inhalation volumes. A novel inhalation device tailored for use in neonates, infants and children and adapted to provide said slow, controlled flow rates with a simplified jet nebuliser set-up is disclosed, together with kits comprising the device

The invention relates to an isoflurane based tranquilizing drug. The isoflurane based tranquilizing drug includes a medicament and a drug carrier, wherein the medicament is isoflurane. The drug carrier comprises a water-absorbing material and a shell. The water-absorbing material is used for carrying isoflurane, and the shell is used for coating the water-absorbing material to avoid isoflurane volatilization. The shell is provided with an opening for volatilizing isoflurane at the opening in the treatment process, and the opening is provided with a sealing device. The isoflurane based tranquilizing drug provided by the invention is an inhaled drug accepted by breathing, has fast tranquilizing speed and small side effect, and the drug subsides quickly after taking effect, and does not affect the normal life and work of drug users. In addition, the isoflurane based tranquilizing drug has low bioconversion rate and minimal influence to liver and kidney functions, and is still suitable for patients with incomplete liver and kidney functions.